The role of the polyomavirus BK (BKV) large
tumor antigen (L-Tag) as a target of immune response in patients with
prostate cancer (PCa) has not been investigated thus far. In this study, we comparatively analyzed humoral and cellular L-Tag-specific responsiveness in age-matched patients bearing PCa or
benign prostatic hyperplasia, expressing or not expressing BKV L-Tag-specific sequences in their tissue specimens, and in non-age-matched healthy individuals. Furthermore, results from patients with PCa were correlated to 5-year follow-up clinical data focusing on evidence of biochemical recurrence (BR) after surgery (
prostate specific antigen level of ≥0.2 ng/ml). In peripheral blood mononuclear cells (PBMC) from patients with PCa with evidence of BR and BKV L-Tag-positive
tumors, stimulation with
peptides derived from the BKV L-Tag but not those derived from Epstein-Barr virus, influenza virus, or cytomegalovirus induced a peculiar
cytokine gene expression profile, characterized by high expression of
interleukin-10 (IL-10) and
transforming growth factor β1 and low expression of
gamma interferon genes. This pattern was confirmed by
protein secretion data and correlated with high levels of anti-BKV L-Tag
IgG. Furthermore, in PBMC from these PCa-bearing patients, L-Tag-derived
peptides significantly expanded an IL-10-secreting CD4(+) CD25(+(high)) CD127(-) FoxP3(+) T cell population with an effector memory phenotype (CD103(+)) capable of inhibiting proliferation of autologous anti-CD3/CD28-triggered CD4(+) CD25(-) T cells. Collectively, our findings indicate that potentially tolerogenic features of L-Tag-specific immune response are significantly associated with
tumor progression in patients with BKV(+) PCa.